Arcticzymes Technologies Asa · OSL:AZT
Arcticzymes Technologies Asa — Pareto Healthcare Conference 2021
11 slides from Arcticzymes Technologies Asa's conference presentation, September 2021
Slide 1: ArcticZymes Technologies - Shaped by the Arctic
ArcticZymes Technologies Shaped by the Arctic September 2021
Slide 2: Specialist supplier of best-in-class novel enzymes
Specialist supplier of best-in-class novel enzymes Innovative Offering B2B and OEM sales Performance • Novel enzymes technology • Broad customer base and long- • Profitable & sales rapidly growing • Focus on high-quality, robust term commercial relationships • Forward leaning growth strategy manufac
Slide 3: Our Novel Enzyme Products
Our Novel Enzyme Products Focus on enzymes that manipulate DNA, for example: Therapeutics Salt Active Nuclease Solves Main Challenge • Cell & gene therapy • Cuts and destroys DNA/RNA • Optimal to purify virus in a high salt environment • Viral vaccines • Novel feature - active in high salt Benefits
Slide 4: Innovations and Molecular Enzyme Market
Innovations and Molecular Enzyme Market Estimated value $1.2 Bil (2021) - therapeutic utility will accelerate growth 25 Existing Enzymes Pipeline Enzymes 20 Proteinases Ligases Other Enzymes 15 (e.g. Nucleases) CAGR% Reverse Polymerases Transcriptases 10 Phosphatases 5 0 0 50 100 150 200 250 300 350
Slide 5: Target Markets & Customers
Target Markets & Customers Serving attractive & growing markets 40 Therapeutics Gene therapy & DNA 30 vaccine manufacturers CAGR (%) Molecular Research 20 Research kit manufacturers Molecular Diagnostics 10 Commercial diagnostic test developers 0 0 1 2 3 4 5 6 7 8 9 10 Market size Billion USD 5 [Sou
Slide 6: Our Customers
Our Customers ArcticZymes is a trusted critical raw material supply Worldwide reach Over 300 customers 100,000´s researchers/clinics Our customer’ ArcticZymes Our Customers Customers Component Other Companies End Users supplier (B2B) (B2C) Our Business Dynamics • Large volume bulk sales (often >1MNO
Slide 7: Financial Performance
Financial Performance Annual Growth and Profitable Sales contribution (2021) Quarterly Rolling 12 Month Sales 140 Therapeutics Research Diagnostics 30 % 23 % 47 % Annual Revenue Target 2021 Last 12 month revenues (MNOK) 120 Previous Target 2023 Quarterly sales and EBITDA margins 100 45 80 Sales 40 E
Slide 8: Growth Strategy
Growth Strategy European’s leading one-stop-shop novel enzyme supplier Simplified Workflow (Molecular Diagnostics) Value chain (Technology) Molecular Proteinase Reverse Transcriptases, Cod UNG, rSAP, Research Polymerases Ligases, etc.. Molecular Tools e Glu Molecular Diagnostics Test & Assays Therap
Slide 9: Summary
Summary High Growth Accelerate Build Long-Term Business Expansion Shareholder Value About leverage existing Broaden product range: Driven by sustainable and new long-term B2B • Bolt and build via M&A profitablity and topline relationships • Ramp up innovation growth pipeline & operations 9
Slide 10: Thank you
ArcticZymes Technologies
Slide 11: Disclaimer
Disclaimer This presentation contains certain forward-looking information and statements. Such forward-looking information and statements are based on the current, estimates and projections of the Company or assumptions based on information currently available to the Company. Such forward-looking in
ArcticZymes Technologies — Pareto Healthcare Conference 2021 on 6ix